Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSeeing Machines Regulatory News (SEE)

Share Price Information for Seeing Machines (SEE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4.82
Bid: 4.785
Ask: 4.845
Change: 0.09 (1.90%)
Spread: 0.06 (1.254%)
Open: 4.795
High: 4.86
Low: 4.785
Prev. Close: 4.73
SEE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Glaucoma Device Demonstrated

8 May 2007 07:02

Seeing Machines Limited08 May 2007 8 May 2007 Seeing Machines Limited ("Seeing Machines" or the "Company") SEEING MACHINES DEMONSTRATES GLAUCOMA DEVICE AT ARVO Seeing Machines (AIM: SEE), a leading developer of advanced computer basedimaging software systems, announces today that the Company is demonstrating theTrueField Analyzer(R) at the Association for Research in Vision and Ophthmalogy(ARVO) Annual Meeting in Florida from May 6-9 2007. The TrueField Analyzer(R)is the Company's revolutionary new medical device to assist doctors in detectingand managing glaucoma and other eye diseases. Seeing Machines is attending ARVO with the Company's key research partners fromthe Research School of Biological Sciences at the Australian NationalUniversity. The ARVO appearance of the TrueField Analyzer(R) is the first publicdemonstration of the device to the general Ophthmalogy community. TheOphthmalogy market will be the key market for the device when it is releasedcommercially. Nick Cerneaz, CEO of Seeing Machines, commented: "Attending this conference isvery exciting for all those who have worked on the development of TrueField andit's exciting for us to be showing the device to its intended users and gettingtheir feedback on our progress to date." Further information about the TrueField Analyzer(R) can be obtained from the website: www.truefield-analyzer.com. Further information about Seeing Machines canbe obtained from the company website www.seeingmachines.com. --- ENDS --- Enquiries:Seeing Machines Limited Insinger de Beaufort Parkgreen CommunicationsNick Cerneaz, CEO Peter Ward Victoria Thomas+61 (0) 2 6125 6501 +44 (0) 20 7190 7015 +44 (0) 20 7851 7480www.seeingmachines.com Notes to editors: About Seeing Machines Seeing Machines is an award winning Technology Company which focuses on visionbased human machine interfaces. Formed in 2000 in Canberra, Australia, SeeingMachines' purpose is to commercialise its computer-vision across a range ofindustries and applications. Seeing Machines deliver advanced computer vision solutions for researches anddevelopers in human factors, transportation safety, computer human interaction,robotics, medical research and psychology. The flagship product faceLAB(TM)provides an automated and contact-free gaze and head tracking technology, itsolves the problem of observing human behaviour naturally, non-intrusively andwith a high degree of accuracy and usability. Building on these unique facetracking and pupil measurement and monitoring capabilities, the TrueFieldAnalyzer(R) is a development undertaken by Seeing Machines in partnership withcolleagues from the Research School of Biological Sciences (RSBS) at theAustralian National University (ANU). The TrueField Analyzer(R) offers a new objective method to help doctors diagnoseand manage a range of eye diseases including glaucoma, age related maculardegeneration and diabetic retinopathy. Glaucoma affects about 2-3% of thepopulation over 40 years of age and is a leading source of blindness. Unlikemost other devices available to the clinician the TrueField Analyzer is acompletely objective test and it is quick and easy for patients and techniciansalike. The device measures both eyes concurrently and due to the reliabilitythat arises from the objective nature of the test, it has the potential tobecome a new 'gold standard' in the measurement of visual field defects and thusin the diagnosis and management of disease such as glaucoma. Seeing Machines' faceLAB(TM) product is a computer vision system that is able tomeasure the orientation and position of a human head, as well as detect blinksand estimate gaze-direction. It achieves all of this completely visually througha stereo camera system connected to advanced image processing software, with noattachments required on the subject. The product is designed to allow humanfactors researchers and designers assess the interaction of an operator in anenvironment and this finds application in designing operator environments, suchas cockpits for cars, trucks, trains, and aeroplanes for instance, and otherindustrial design applications, as well as medical and psychological researchsituations. The technology also has application in monitoring automobiledrivers and if it detects drowsiness or that the driver is distracted and theirattention has been diverted from the road, an alarm can be raised to alert thedriver to either pull over and rest in the case of drowsiness or to pay moreattention to the road. faceLAB(TM) works in real-time, enabling the behaviour of a subject to betracked. This technology is paving the way in promoting safer driving conditionsand works to enhance the driving experience and to eliminate accidents causedthrough driver drowsiness or distraction. There are many different sectors that can benefit from this revolutionarysoftware, for which it has been developed, including: automotive; academicresearch; medicine/healthcare; defence; autostereoscopy (next generationdisplays); sport; and games. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
6th Oct 20227:00 amRNSExclusive agreement with Magna & US$65m investment
15th Sep 20228:50 amRNSTown Hall (Revised Date)
9th Sep 20227:30 amRNSPostponement of London presentation
16th Aug 20227:00 amRNSSeeing Machines London presentation
15th Aug 20227:00 amRNSFY2022 trading update
2nd Aug 202212:30 pmRNSInvestor newsletter update
16th Jun 20227:00 amRNSSeeing Machines awarded additional OEM program
6th Jun 20227:22 amRNSNew Tier One contract takes OEM customers to 10
10th May 20227:00 amRNSSeeing Machines appointment with Japanese OEM
9th May 20227:00 amRNSSeeing Machines collaboration in optics technology
21st Apr 20227:00 amRNSCollaboration with leading systems supplier
20th Apr 20227:00 amRNSSeeing Machines inks additional Occula NPU licence
30th Mar 20227:00 amRNSHalf-year results and financial report
28th Feb 202211:45 amRNSDirector/PDMR Shareholding
24th Feb 20227:00 amRNSSeeing Machines, Air Ambulance Victoria contract
23rd Feb 20227:00 amRNSHalf year trading update
16th Feb 20229:00 amRNSHolding(s) in Company
24th Jan 20227:00 amRNSIIHS Implementation of New Safety Ratings
6th Jan 202212:30 pmRNSSeeing Machines & Qualcomm to demo at CES 2022
6th Jan 202210:01 amRNSAmbarella & Seeing Machines Collaboration
5th Jan 202211:02 amRNSOmniVision & Seeing Machines ASIC Collaboration
31st Dec 20217:00 amRNSWithdrawal from in-person attendance at CES 2022
23rd Dec 202110:30 amRNSIssue of Performance Rights
16th Dec 20218:30 amRNSResult of AGM
16th Dec 20217:00 amRNSLargest Driver & Occupant Monitoring System Award
15th Dec 20218:08 amRNSFY 2021 Annual Report
14th Dec 202110:30 amRNSDirector/PDMR Shareholding
13th Dec 202110:00 amRNSDirector/PDMR Shareholding
9th Dec 20219:15 amRNSDirector/PDMR Shareholding
6th Dec 202110:00 amRNSNotice of AGM
1st Dec 202112:15 pmRNSHolding(s) in Company
1st Dec 202112:00 pmRNSDirector/PDMR Shareholding
1st Dec 20217:00 amRNSTotal Voting Rights
26th Nov 202110:00 amRNSDirector/PDMR Shareholding
26th Nov 20219:48 amRNSDirector/PDMR Shareholding
24th Nov 202110:52 amRNSIssue of Equity
24th Nov 20217:00 amRNSYear End Results
23rd Nov 20217:00 amRNSResult of Fundraise
22nd Nov 20214:37 pmRNSRetail Offer via PrimaryBid
22nd Nov 20214:35 pmRNSProposed Fundraise to Raise a Minimum of US$40m
15th Nov 20217:00 amRNSCollins Aerospace & Seeing Machines Collaboration
10th Nov 20217:00 amRNSChange of Nominated Adviser
8th Nov 20217:00 amRNSBipartisan infrastructure legislation
2nd Nov 20217:00 amRNSInvestor Presentation
18th Oct 20217:37 amRNSNotice of Results
13th Oct 20217:00 amRNSSeeing Machines establishes European sales team
11th Oct 20217:00 amRNSGlobal Framework Agreement with Shell
23rd Sep 20212:00 pmRNSSeeing Machines unveils its Occula® NPU
16th Aug 20217:13 amRNSLeading software provider integrates Guardian
11th Aug 20217:00 amRNSBipartisan Senate legislation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.